Sutro Biopharma (NASDAQ:STRO) Raised to "Hold" at Wall Street Zen

Key Points

• Sutro Biopharma (NASDAQ:STRO) received an upgrade from Wall Street Zen, changing its rating from "sell" to "hold".
• The stock currently has an average target price of $4.47 with a consensus rating of "Hold" based on multiple analysts' evaluations.
• Despite a recent quarterly earnings report that exceeded expectations, Sutro Biopharma reported a negative net margin of 201.32% and a return on equity of -852.70%.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday.

A number of other brokerages also recently commented on STRO. Bank of America cut their price objective on shares of Sutro Biopharma from $1.00 to $0.80 and set an "underperform" rating for the company in a research report on Monday, May 19th. Wells Fargo & Company cut their price target on shares of Sutro Biopharma from $4.00 to $3.00 and set an "equal weight" rating for the company in a report on Tuesday, August 12th. Finally, Piper Sandler raised shares of Sutro Biopharma from a "neutral" rating to an "overweight" rating and set a $2.00 price objective on the stock in a report on Monday, June 16th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Sutro Biopharma currently has an average rating of "Hold" and a consensus target price of $4.47.

Sutro Biopharma Stock Performance

Sutro Biopharma stock traded up $0.05 during trading hours on Friday, reaching $0.90. 616,668 shares of the stock were exchanged, compared to its average volume of 522,521. The stock has a market cap of $76.53 million, a P/E ratio of -0.36 and a beta of 1.57. Sutro Biopharma has a 52-week low of $0.52 and a 52-week high of $4.60. The firm's 50 day moving average is $0.86 and its 200 day moving average is $0.85.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.39) by $0.25. The company had revenue of $63.74 million during the quarter, compared to the consensus estimate of $14.55 million. Sutro Biopharma had a negative net margin of 201.32% and a negative return on equity of 852.70%. Equities research analysts expect that Sutro Biopharma will post -2.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Sutro Biopharma

Large investors have recently added to or reduced their stakes in the business. Nuveen LLC acquired a new stake in Sutro Biopharma in the 1st quarter valued at about $189,000. Vontobel Holding Ltd. grew its stake in Sutro Biopharma by 100.0% in the 1st quarter. Vontobel Holding Ltd. now owns 50,000 shares of the company's stock valued at $33,000 after acquiring an additional 25,000 shares during the last quarter. Acadian Asset Management LLC lifted its holdings in Sutro Biopharma by 78.9% in the 1st quarter. Acadian Asset Management LLC now owns 3,134,586 shares of the company's stock valued at $2,037,000 after purchasing an additional 1,382,661 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Sutro Biopharma by 82.7% during the 4th quarter. BNP Paribas Financial Markets now owns 150,758 shares of the company's stock worth $277,000 after purchasing an additional 68,234 shares during the last quarter. Finally, RA Capital Management L.P. acquired a new stake in shares of Sutro Biopharma during the 1st quarter worth about $2,885,000. 96.99% of the stock is owned by institutional investors and hedge funds.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.